FDA Biomarker Qualification Program

Under FDA’s Biomarker Qualification Program (BQP), a biomarker is “qualified” when FDA issues a formal regulatory determination that the biomarker is reliable for a specific, defined context of use (COU) in drug development — meaning any sponsor can rely on it for that COU, in any development program, without independently justifying its suitability to FDA each time. This is a different, and much higher, bar than a biomarker that FDA has simply accepted or not objected to within one sponsor’s single trial or program.

Operational definition

A biomarker qualification exists, in the BQP sense, when all of the following are true:

• FDA (jointly through the Center for Drug Evaluation and Research, CDER, and the Center for Biologics Evaluation and Research, CBER) has completed formal review under Section 507 of the Food, Drug & Cosmetic Act — added by the 21st Century Cures Act (signed into law December 13, 2016) — and issued a qualification decision.
• The qualification is scoped to a specific context of use (COU): the biomarker category (e.g. diagnostic, prognostic, predictive, pharmacodynamic/response, safety, susceptibility/risk, or monitoring, per the FDA-NIH BEST Resource glossary), the population, and exactly how the biomarker will be used and interpreted in a regulatory submission.
• Once qualified for that COU, the biomarker is portable: any sponsor may use it for that COU across multiple, unrelated drug development programs without re-litigating its scientific validity with FDA each time.

By contrast, a biomarker a sponsor proposes and FDA does not object to — or even affirmatively accepts — within a single Investigational New Drug (IND) application or a single trial’s design is not a BQP qualification. That acceptance is a program-specific regulatory judgment, made by one review division for one sponsor’s one program; it carries no weight for a different sponsor, a different drug, or even the same sponsor’s next program, and must be independently justified again if reused.

The three-stage qualification process

Section 507 formalized biomarker qualification into a staged submission process, with FDA guidance (finalized 2020) setting target review timeframes for each stage:

• Letter of Intent (LOI) — target 3 months. The requestor (often a consortium rather than a single company) describes the proposed biomarker, its intended COU, how it will be measured, and the unmet development need it addresses. FDA responds with an accept/not-accept decision plus feedback.
• Qualification Plan (QP) — target 6 months. Sets out the evidentiary plan: what data will be generated or compiled, and how it will support the proposed COU.
• Full Qualification Package (FQP) — target 10 months. The complete evidentiary submission; FDA’s review culminates in a qualification decision (typically issued as guidance) or a determination that qualification is not supported.

FDA maintains a public DDT (Drug Development Tool) Qualification Project Search database, and the 21st Century Cures Act’s transparency provisions require FDA to publish and update submission status information at least twice a year — a direct response to qualification’s cross-program legal weight: because a qualified biomarker becomes usable by sponsors who were never party to the original submission, the process and its status are required to be publicly visible in a way a single sponsor’s internal COU justification is not.

Worked example

Total Kidney Volume (TKV) in ADPKD. In August 2015, FDA (and the European Medicines Agency, in parallel) qualified Total Kidney Volume as a prognostic enrichment biomarker for selecting patients at high risk of progressive renal function decline for inclusion in interventional trials for autosomal dominant polycystic kidney disease (ADPKD). The submission came from the Polycystic Kidney Disease Outcomes Consortium (PKDOC), a consortium convened by the Critical Path Institute (C-Path), and drew on pooled longitudinal imaging data across multiple patient registries and cohort studies. Because TKV is qualified for that specific COU, any sponsor developing an ADPKD therapy can use it for trial enrichment without separately re-proving its prognostic validity to FDA — the qualification, not any one sponsor’s data package, does that work once.

A structurally similar pattern exists on the safety side of the program: several FDA-qualified nonclinical biomarkers exist for early detection of drug-induced organ injury (kidney injury biomarkers among them), developed through C-Path’s Predictive Safety Testing Consortium (PSTC) — again submitted by a multi-sponsor consortium precisely because the resulting qualification needed to be usable across many companies’ distinct nonclinical safety programs, not just one.

Counter-example

A sponsor develops a genomic biomarker to enrich enrollment in its own Phase 3 oncology trial, documents the scientific rationale in its IND, and the reviewing division does not object. That biomarker is not BQP-qualified, even though FDA effectively accepted its use. The acceptance lives inside that one IND, for that one sponsor’s one program; a competitor developing a different drug in the same indication cannot point to it and must independently justify the same biomarker’s use to FDA from scratch — exactly the re-review burden formal qualification is designed to remove.

Why the distinction matters for research administration

Research administrators and study teams working across multi-site or consortium-based translational programs need to know which category a candidate biomarker falls into before writing it into a protocol or grant budget: a qualified biomarker can be adopted with citation to FDA’s qualification decision, while a non-qualified but “accepted” biomarker still requires its own validation and justification package within that specific program, with associated time and cost. The Biomarker Qualification Program is one of three parallel Drug Development Tool (DDT) qualification pathways under Section 507 — the others cover Clinical Outcome Assessments (COAs) and animal model qualification — all sharing the same underlying logic of converting a program-specific regulatory judgment into a reusable, cross-program regulatory tool.

Related terms

• Clinical Outcome Assessment (COA) — the parallel DDT qualification pathway for outcome measures rather than biological/physiological markers.
• Surrogate Endpoint Validation — a qualified biomarker is sometimes, but not automatically, also validated as a surrogate endpoint capable of supporting approval; the two are related but legally distinct determinations.
• Estimand Framework — defines precisely what a trial is trying to estimate about a treatment effect; a qualified biomarker used as an endpoint still needs its estimand specified within the individual trial.
• Accelerated Approval — the regulatory pathway that most often relies on a surrogate or intermediate clinical endpoint, which may or may not derive from a BQP-qualified biomarker.